ASH 2020 | MB-106 as a novel CD20-targeted CAR-T treatment in R/R B-NHL
Mazyar Shadman, MD, Fred Hutchinson Cancer Research Center, Seattle, WA, discusses the ongoing Phase I/II study (NCT03277729) aiming to investigate the efficacy and safety of CD20 CAR T-cell therapy in high-risk B-cell non-Hodgkin lymphomas (B-NHLs). Patients were treated with MB-106, a CD20-targeted CAR-T. With the initial treatment lacking clinical responses, the manufacturing process underwent a major revision. Target cell doses were then achieved in all patients. While many participants experienced treatment-emergent adverse events (TEAEs), none of them were severe and no dose-limiting toxicity (DLT) were reported. Robust CAR-T expansion was seen in most of the patients, many of whom achieved partial or complete remission. Following the revision of the manufacturing process, the results of this ongoing study suggest an extremely favorable safety profile of CD20 CAR-T in high-risk NHLs. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Transcript (edited for clarity)
We are very excited to present for the first time our data from our CD20-targeted CAR-T trial, which is a full human, third generation CAR-T, meaning that both 4-1BB and CD28 co-stimulatory domains are present on this CAR-T and this is a CAR that’s developed by Dr Brian Till at the Hutch.
So this Phase I study, we’re looking at patients with CD20-positive B non-Hodgkin lymphoma...
We are very excited to present for the first time our data from our CD20-targeted CAR-T trial, which is a full human, third generation CAR-T, meaning that both 4-1BB and CD28 co-stimulatory domains are present on this CAR-T and this is a CAR that’s developed by Dr Brian Till at the Hutch.
So this Phase I study, we’re looking at patients with CD20-positive B non-Hodgkin lymphoma. And what we’re presenting at the meeting is results after treating the first nine patients. And we have seen very promising efficacy data with low-grade lymphomas that we have treated, and more importantly, a very encouraging safety profile. We’re really not seeing any neurotoxicity of any grades, and also really the new process that we have developed, we’ve only had one patient with grade one cytokine release syndrome.
So very small numbers and this is just the beginning, but the signal that we’re seeing, both for efficacy and safety, are really encouraging. The study is ongoing, and we recently added CLL as a new eligibility indication to this study. So, yeah. It’s a totally outpatient treatment and we are hoping that with this preliminary result in the first study that we are currently enrolling, we move forward to a Phase II study, a Phase I/II study, a multicenter study, hopefully in the future.
Read more...
